Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

(2018) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

(2018) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

(2018) E Michael Lewiecki et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

(2017) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

(2017) Bente L Langdahl et al.   LANCET

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

(2017) Kenneth G. Saag et al.   NEW ENGLAND JOURNAL OF MEDICINE

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

(2016) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

(2015) S. Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody

(2014) Xiaodong Li et al.   ENDOCRINOLOGY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

(2013) Desmond Padhi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis

(2010) H. M. Macdonald et al.   OSTEOPOROSIS INTERNATIONAL